ஜொனாதன் மோ News Today : Breaking News, Live Updates & Top Stories | Vimarsana

PhaseBio Pharmaceuticals, Inc.: PhaseBio Announces Dosing of First Patient in European Union as Part of REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor
with antiplatelet therapy being a core treatment to prevent cardiovascular events
The lack of reversal agents for patients taking antiplatelet therapies who require urgent surgery or experience a major bleeding event remains a critical unmet need
Bentracimab (PB2452) has demonstrated immediate and sustained reversal of the antiplatelet effects of ticagrelor in both Phase 1 and Phase 2 clinical trials
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that in conjunction with its financing and co-development partner for the European Union and China, SFJ Pharmaceuticals, PhaseBio has expanded its pivotal Phase 3 R ....

San Diego , United States , United Kingdom , John Sharp , John Lee , Brilinta Brilique , Phasebio Pharmaceuticals Inc , Drug Administration , Exchange Commission , Canale Communications Inc , European Union , Phasebio Pharmaceuticals , Jonathan Mow , Chief Medical Officer , Ticagrelor Intervention Trial , New England Journal , Breakthrough Therapy Designation , Biologics License Application , Looking Statements , Private Securities Litigation Reform Act , Quarterly Report , Financial Officer , சான் டியாகோ , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , ஜான் கூர்மையான ,